



Pros, Cons and Perspectives of SARS-CoV-2/COVID-19 Vaccines and Vaccination

Guest Editors:

Dr. Flavia Ferrantelli

National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy

Dr. Chiara Chiozzini

National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy

Deadline for manuscript submissions:

closed (1 February 2023)

Message from the Guest Editors

The need for an effective anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) vaccine has been clear since the beginning of the global pandemic, in early 2020. Within one year from SARS-CoV-2 identification, with hundreds of ad hoc vaccine studies carried out and tens of candidate vaccines advanced to clinical testing, a few novel vaccines have been approved for emergency use in humans. This unprecedented extraordinary scientific and financial effort has thrived on freely available basic science data, leading to the successful exploitation of innovative platforms against key viral targets. Nonetheless, several questions remain open as to whether the newly approved, or other yet-to-be-identified, vaccines will be able to control the COVID-19 pandemic and for how long, and whether vaccine safety will be acceptable in the long run.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)